Shopping Cart
- Remove All
- Your shopping cart is currently empty
Mirvetuximab (M9346A) is a novel folate receptor α (FRα) monoclonal antibody targeting anti-FOLR1 (folate receptor 1). Mirvetuximab soravtansine is often conjugated with platinum compounds or other compounds to form antibody-drug conjugates for the treatment of ovarian cancer and other FRα-positive cancers.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $322 | In Stock | |
5 mg | $788 | In Stock | |
10 mg | $1,280 | In Stock |
Description | Mirvetuximab (M9346A) is a novel folate receptor α (FRα) monoclonal antibody targeting anti-FOLR1 (folate receptor 1). Mirvetuximab soravtansine is often conjugated with platinum compounds or other compounds to form antibody-drug conjugates for the treatment of ovarian cancer and other FRα-positive cancers. |
Alias | M9346A |
Molecular Weight | 148 kDa (average) |
Cas No. | 1453084-36-0 |
Storage | store at low temperature | store at -80°C | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.